Silence Therapeutics’ Partner Quark Pharmaceuticals Announces Results From Phase 2 PF-04523655 Study In Diabetic Macular Edema
Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") a leading global RNA interference (RNAi) therapeutics company, announces today that its partner, Quark Pharmaceuticals, has received results from a prospective randomized Phase 2 trial, the DEGAS study. The study evaluated the safety and efficacy of PF-04523655 (RTP801I- 14) in patients with diabetic macular edema (DME). PF-04523655 incorporates Silence's AtuRNAi technology and was sub-licensed to Pfizer Inc. by Quark Pharmaceuticals.